SCHEMBL6128166

SCHEMBL6128166

CC1C[C@H](C(=O)O)N(Cc2ccccc2)[C@]1(C)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRM6 O15303 1/20 0.49
GRM2 Q14416 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
LMNA P02545 1/20 0.41
OPRK1 P41145 2/20 0.39
OPRM1 P35372 1/20 0.39
ACE P12821 1/20 0.39
CYP2D6 P10635 1/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
RAB9A P51151 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MAPT P10636 1/20 0.38
S1PR1 P21453 1/20 0.38
S1PR5 Q9H228 1/20 0.38
AMPD2 Q01433 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5965412 1.00 GRM6 (0.49) GRM6GRM2MEN1KMT2ALMNA
SCHEMBL5965414 1.00 GRM6 (0.49) GRM6GRM2MEN1KMT2ALMNA
SCHEMBL6647307 0.87 GRM6 (0.48) GRM6GRM2MEN1KMT2ALMNA
SCHEMBL5451611 0.75 GRM6 (0.52) GRM6GRM2OPRK1ACEALDH1A1
SCHEMBL5550768 0.75 GRM6 (0.52) GRM6GRM2OPRK1ACEALDH1A1
SCHEMBL22443390 0.74 GRM6 (0.51) GRM6GRM2OPRK1ACECYP2D6
SCHEMBL25197531 0.71 GRM6 (0.43) GRM6GRM2MEN1KMT2AOPRK1
SCHEMBL29088227 0.71 GRM6 (0.43) GRM6GRM2MEN1KMT2AOPRK1
SCHEMBL6683379 0.71 MAPT (0.46) GRM6KMT2ALMNAACEALDH1A1
SCHEMBL9356296 0.70 CHRM2 (0.50) GRM6MEN1KMT2ALMNAOPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3699176-A2 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2020-08-26 EP disclosed
US-20200123132-A1 ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC 2020-04-23 US disclosed
US-10344019-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2019-07-09 US disclosed
EP-3284741-A1 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2018-02-21 EP disclosed
EP-2640719-B1 ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC (US) 2017-05-10 EP disclosed
US-20150353529-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2015-12-10 US disclosed
US-9156823-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2015-10-13 US disclosed
US-20140018313-A1 ANTIVIRAL COMPOUNDS Gelead Sciences, Inc. 2014-01-16 US disclosed
EP-2640719-A2 ANTIVIRAL COMPOUNDS Gilead Sciences, Inc. (US) 2013-09-25 EP disclosed
WO-2012068234-A2 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018313-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 GRM6 3534/4885GRM2 4537/4885MEN1 4292/4885
US-10344019-B2 Antiviral compounds MAVS, EIF2AK2, ZC3HAV1 GRM6 3534/4885GRM2 4537/4885MEN1 4292/4885
US-20150353529-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 GRM6 3534/4885GRM2 4537/4885MEN1 4292/4885
US-20200123132-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 GRM6 3534/4885GRM2 4537/4885MEN1 4292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.